Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Under $5.00 stocks -- Ignore unavailable to you. Want to Upgrade?

To: JakeStraw who wrote (42)	5/16/2010 11:11:43 PM
From: Gary Mohilner	Respond to of 45

Take a look at GNVC, if the partnership they're after for their lead cancer drug, TNFerade, occurs this year, they should reach the high previously established prior to the drug's failure in Pancreatic Cancer. If you recognize that many other already approved drugs failed in Pancreatic Cancer, this shouldn't be that big a surprise, but it was the lead trial. Look at results to date in Esophageal, Head and Neck, and Melanoma, I believe you'll see a drug that may be approved in time for many solid tumors including Pancreatic once the right trial protocols been established. At the current $.60 a return to the annual high would be over a 5 banger. Gary